The results from last school year’s MAP tests show that most students are still performing below their pre-pandemic peers.
Enjoy a brainteaser from the Today team ...
The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback